Skip to main content

Advertisement

SpringerLink
Log in

Bone metabolism in 2012

Novel osteoporosis targets

  • Year in Review
  • Published:

From Nature Reviews Endocrinology

View current issue Sign up to alerts

Researchers are trying to develop more efficient and safer antifracture treatments. Besides the ongoing promising clinical trials involving antibodies to the Wnt antagonist sclerostin or inhibition of the osteoclast enzyme cathepsin K, the year 2012 has seen several novel osteoporosis targets identified by using different methodological approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Current and future antifracture treatments.

References

  1. Estrada, K. et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat. Genet. 44, 491–501 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Zheng, H. F. et al. WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS Genet. 8, e1002745 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ralston, S. H. & Uitterlinden, A. G. Genetics of osteoporosis. Endocr. Rev. 31, 629–662 (2010).

    Article  CAS  PubMed  Google Scholar 

  4. Andrew, T., Antioniades, L., Scurrah, K. J., Macgregor, A. J. & Spector, T. D. Risk of wrist fracture in women is heritable and is influenced by genes that are largely independent of those influencing BMD. J. Bone Miner. Res. 20, 67–74 (2005).

    Article  PubMed  Google Scholar 

  5. Hayashi, M. et al. Osteoprotection by semaphorin 3A. Nature 485, 69–74 (2012).

    Article  CAS  PubMed  Google Scholar 

  6. Zaidi, M. & Iqbal, J. Translational medicine: Double protection for weakened bones. Nature 485, 47–48 (2012).

    Article  CAS  PubMed  Google Scholar 

  7. Sjogren, K. et al. The gut microbiota regulates bone mass in mice. J. Bone Miner. Res. 27, 1357–1367 (2012).

    Article  PubMed  Google Scholar 

  8. Ley, R. E. et al. Evolution of mammals and their gut microbes. Science 320, 1647–1651 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Cho, I. et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 488, 621–626 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Boonen, S. et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N. Engl. J. Med. 367, 1714–1723 (2012).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Bone and Arthritis Research, Vita Stråket 11, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, 413 45, Sweden

    Claes Ohlsson

Authors
  1. Claes Ohlsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ohlsson, C. Novel osteoporosis targets. Nat Rev Endocrinol 9, 72–74 (2013). https://doi.org/10.1038/nrendo.2012.252

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2012.252

  • Springer Nature Limited

This article is cited by

Search

Navigation